SANAHealthcare · BiotechnologyThe 9 Wall Street analysts covering Sana Biotechnology, Inc. hold a median 12-month price target of $7 — +172.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 36 of 100 as at 31 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Sana Biotechnology, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (83): Reported profit is backed by cash, and the company is not expanding recklessly.
Volatility (20): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on SANA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +172.4% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 14 Aug 2026 | B of A Securities | Maintains | Buy | $7.00 → $6.00 |
| 14 Apr 2026 | Wedbush | Maintains | Outperform | $6.00 → $7.00 |
| 14 Apr 2026 | Wedbush | Maintains | Outperform | — |
| 4 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 6 Jan 2026 | B of A Securities | Maintains | Buy | — |
| 7 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 7 Nov 2025 | Wedbush | Maintains | Outperform | — |
| 30 Oct 2025 | Citizens | Maintains | Market Outperform | — |
| 24 Sept 2025 | Wedbush | Initiates | Outperform | — |
| 3 July 2025 | Morgan Stanley | Assumes | Overweight | $12 |
| 24 June 2025 | JMP Securities | Reiterates | Market Outperform | — |
| 24 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 18 Mar 2025 | Citizens Capital Markets | Upgrade | Market Outperform | — |
| 18 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 Mar 2025 | Jefferies | Initiates | Buy | — |
| 8 Jan 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 8 Jan 2025 | TD Cowen | Upgrade | Buy | — |
| 27 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 Nov 2024 | HC Wainwright & Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
SANA appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 30 Oct 2026, Sana Biotechnology, Inc. returned −47.6% against +12.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 87% of US stocks
Cheaper than 19% of US stocks
Cheaper than 79% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 9% of US stocks
Higher than 14% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Sana Biotechnology, Inc. has a market value of $769.4M and an enterprise value of $734.7M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$211.8M.
Diluted earnings per share, trailing twelve months: $−0.76.
Free cash flow in the twelve months to 30 June 2026: −$135.1M.
Trailing P/E: −2.7×; forward P/E: −4.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Sana Biotechnology, Inc. employs 142 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Sana Biotechnology, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
A Seeking Alpha article highlights Sana Biotechnology’s T1D assets, reporting that early UP421 data showed durable insulin production without immunosuppression. It also notes that the company has about five quarters of cash runway at its current burn rate.
Why it matters — SANA watchers may weigh the reported early asset results against the company’s limited runway and reliance on near-term pipeline progress.
Sana Biotechnology, Inc. presented at the Morgan Stanley 24th Annual Global Healthcare Conference. The item consists of the transcript of that presentation.
Why it matters — SANA watchers would care because the conference transcript offers insight into company management's views and updates shared with the investment community.
Sana Biotechnology, Inc. presented a transcript of its appearance at Citigroup's Biopharma Back to School Summit 2026, as published by Seeking Alpha. The excerpt provides only the headline and source information with no additional details.
Why it matters — A SANA watcher would care because investor presentations at major conferences like Citigroup's summit can provide insight into the company's business strategy and pipeline updates.
Sana Biotechnology, Inc. presented at the Wells Fargo 21st Annual Healthcare Conference, with a transcript of its presentation made available on Seeking Alpha. The item reports on the company's conference participation.
Why it matters — SANA watchers can follow the company's remarks and updates shared during its presentation at a major industry healthcare conference.
A legal firm is reaching out to Sana Biotechnology, Inc. shareholders, encouraging them to contact the firm to discuss their rights and options regarding a potential breach of fiduciary duties by company insiders. The firm notes it would handle any matter on a contingent fee basis, with no out-of-pocket legal costs for shareholders.
Why it matters — SANA watchers would care because the news signals a potential shareholder legal action alleging that company insiders may have breached fiduciary duties.
The 9 Wall Street analysts covering Sana Biotechnology, Inc. have a median 12-month price target of $7, with estimates ranging from $6 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 9 analysts covering Sana Biotechnology, Inc., 8 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Sana Biotechnology, Inc. 36 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Oct 2026, Sana Biotechnology, Inc. ranks 36 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (83 of 100).
No one can know that. What the data says: the median 12-month target from 9 analysts implies +172.4% from the last close, and Ticker Nerd's factor model ranks Sana Biotechnology, Inc. 36 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Sana Biotechnology, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SANA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $12 over the next 12 months.
Sana Biotechnology, Inc. returned -47.6% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Sana Biotechnology Inc. is a biotechnology company focused on creating and delivering engineered cells as medicines.
The most recent item we track (Seeking Alpha, 13 Oct 2026): "Sana Biotechnology: A Shot At Diabetes". A Seeking Alpha article highlights Sana Biotechnology’s T1D assets, reporting that early UP421 data showed durable insulin production without immunosuppression. It also notes that the company has about five quarters of cash runway at its current burn rate.
Sana Biotechnology Inc. is a biotechnology company focused on creating and delivering engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms designed to address serious diseases with unmet treatment needs, including type 1 diabetes, B cell-mediated autoimmune diseases, oncology, and other immune-related conditions. Its work centers on modifying, replacing, or repairing cells to support next-generation therapeutic approaches, with research and development spanning cell therapy, gene delivery, and immune evasion technologies. Sana Biotechnology operates as a clinical-stage company and does not yet market approved commercial therapies, making its role in the market primarily centered on innovation, pipeline development, and translational research. Headquartered in Seattle, Washington, the company is part of the broader biotechnology sector, where engineered-cell platforms are an important area of active drug development.
CEO Dr. Steven D. Harr M.D. · 142 employees · United States · https://www.sana.com
